What are Acadia Pharmaceuticals's profit margins?

Gross margin is 91.5% and operating margin is 7.4%, with a 34.3% net margin.

Where does Acadia Pharmaceuticals's income statement data come from?

Every line is extracted from Acadia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Acadia Pharmaceuticals ACAD Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Total revenue	$1.07B+11.9%	$957.8M+31.8%	$726.44M+40.4%	$517.24M+6.8%
Total cost of revenue	$89M+8.7%	$81.84M+96.5%	$41.64M+310%	$10.17M-46.9%
Gross profit	$982.51M+12.2%	$875.96M+27.9%	$684.8M+35.1%	$507.07M+9.0%
Gross margin	91.7%+0.2pp	91.5%-2.8pp	94.3%-3.8pp	98%+2.0pp
Research and development	$328.8M+8.4%	$303.25M-13.8%	$351.62M-2.8%	$361.58M+51.0%
Selling, general and administrative	$548.89M+12.4%	$488.43M+20.1%	$406.56M+10.2%	$369.09M-6.8%
Total costs & expenses	$966.69M+33.0%	$727M-9.1%	$799.82M+8.0%	$740.83M+13.2%
Operating income	$104.81M-54.6%	$230.79M—	——	-$223.6M-31.2%
Operating margin	9.8%-14.3pp	24.1%—	——	-43.2%-8.0pp
Interest expense	$31.72M+24.6%	$25.46M+47.7%	$17.23M+161%	$6.61M+1,018%
Other income (expense), net	$2.37M+30.1%	$1.82M-64.3%	$5.11M+44.2%	$3.54M+73.7%
Gain (loss) on disposal of assets	$0-100%	$146.52M—	$0—	$0—
Income before income taxes	$138.9M-46.2%	$258.08M—	——	-$213.44M-27.4%
Income tax expense	-$252.1M-897%	$31.62M—	——	$2.53M+621%
Net income	$391M+72.7%	$226.45M+469%	-$61.29M+71.6%	-$215.98M-28.7%
Net margin	36.5%+12.8pp	23.6%+32.1pp	-8.4%+33.3pp	-41.8%-7.1pp
Diluted earnings per share	$2.30+69.1%	$1.36+458%	-$0.38+71.6%	-$1.34-27.6%
Basic earnings per share	$2.32+69.3%	$1.37+461%	-$0.38+71.6%	-$1.34-27.6%
Weighted-average shares, diluted	676.9M+1.7%	665.3M+1.5%	655.4M+1.4%	646.4M+0.8%
Weighted-average shares, basic	671.8M+1.5%	662M+1.3%	653.8M+1.1%	646.4M—
Interest Income (Expense), Nonoperating	$31.72M+24.6%	$25.46M+47.7%	$17.23M+161%	$6.61M+1,018%
Depreciation	$871K-5.3%	$920K-36.9%	$1.46M-28.0%	$2.03M-9.4%
Income Taxes Paid, Net	$25.17M+28.9%	$19.52M+234%	$5.85M+167%	$2.19M+111%
Accounts payable	-$5.29M-291%	-$1.35M-128%	$4.8M—	——
Accrued liabilities	-$19.27M-127%	$71.06M-23.7%	$93.17M—	——
Increase (Decrease) in Other Operating Assets	$2.86M+2,541%	-$117K—	——	——
Other liabilities	$1.08M-62.8%	$2.91M-52.1%	$6.07M—	——
Other income, net (Note 6)	$2.37M+30.1%	$1.82M-64.3%	$5.11M+44.2%	$3.54M+73.7%
Payments to Acquire Property, Plant, and Equipment	$4.69M—	——	$50K—	$0-100%
Proceeds from Issuance of Common Stock	$49.88M+629%	$6.85M-72.8%	$25.13M+206%	$8.2M-54.9%
Proceeds from sales and redemptions of investments in debt securities classified as available for sale	$493.53M+50.2%	$328.57M-23.6%	$429.78M-1.5%	$436.42M+3.2%
Revenue From Contract With Customer Excluding Assessed Tax	$1.07B+11.9%	$957.8M+31.8%	$726.44M+40.4%	$517.24M+6.8%
Stock-based compensation	$52.14M-22.2%	$67.05M+0.9%	$66.42M-2.6%	$68.2M+7.2%
EBIT	$104.81M-54.6%	$230.79M—	——	-$223.6M-31.2%
EBITDA	$116.57M-52.7%	$246.68M—	——	-$221.57M-32.7%
EBITDA	$116.57M-52.7%	$246.68M—	——	-$221.57M-32.7%
EBITDA margin	10.9%-14.9pp	25.8%—	——	-42.8%-8.3pp
EBIT	$104.81M-54.6%	$230.79M—	——	-$223.6M-31.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Acadia Pharmaceuticals's profit margins?: Gross margin is 91.5% and operating margin is 7.4%, with a 34.3% net margin.
Where does Acadia Pharmaceuticals's income statement data come from?: Every line is extracted from Acadia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.